Improving patient compliance: A major goal in the management of hypertension

Journal of Clinical Hypertension

Volumn 5, Issue 2, 2003, Pages 127-132

  Neutel, Joel M ^a   Smith, David H G ^a  

^a Orange County Heart Institute and Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDAPAMIDE; PERINDOPRIL; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG CHOICE; DRUG COST; DRUG SAFETY; EDUCATION; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PERIPHERAL EDEMA; POLYPHARMACY; REVIEW;

EID: 0037366519     PISSN: 15246175     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-6175.2003.00495.x     Document Type: Review

References (37)

1. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Hot Study Group. Lancet. 1998;351:1755-1762.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
3. Burt VL, Cutler JA, Higgins M. Trends in the prevalence, awareness, treatment, and control of hypertension in the US population from the Health Examination Surveys. 1960 to 1991. Hypertension. 1995;26:60-69.
4. Marques-Vidal P, Toumilehto J. Hypertension awareness, treatment and control in the community: is the 'role of halves' still valid? J Hum Hypertens. 1997;11(4):213-220.
5. The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-1446.
6. MacMahon S, Petro R, Cutler J, et al. Blood pressure, stroke and coronary heart disease. Part I: prolonged differences in blood pressure: prospective observational studies corrected for the regression delusional bias. Lancet. 1990;335:765-774.
7. Flack JM, Neaton J, Grimm R Jr. Blood pressure and mortality among men with prior myocardial infarction. Multiple Risk Faction Intervention Trial Research Group. Circulation. 1995;92:2437-2445.
8. McCombs JS, Nichol M, Newman C, et al. The costs of interrupting antihypertensive therapy in a Medicaid population. Med Care. 1994;32:214-226.
9. Dusing R, Weisser B, Mengden T, et al. Changes in antihypertensive therapy - the role of adverse effects and compliance. Blood Press. 1998;7;313-315.
10. Jones JK, Gorkin L, Lian JF, et al. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom Population. BMJ. 1995;311:293-295.
11. Taylor Nelson Healthcare. Epson Survey. England Copyright Cardiomonitor, 1992.
12. Moser M. Clarify the message, improve outcome in the management of hypertension. J Clin Hypertens (Greenwich). 2000; 2:71-76.
13. Chobanian A. Effects of beta-blockers and other antihypertensive drugs on cardiovascular risk. Am J Cardiol. 1987;59:1F.
14. Bloom BS. Continuation of initial antihypertensive therapy after one year of therapy. Clin Ther. 1998;20(4):671-681.
15. Moser M. Physician adherence in the management of hypertension. Drug Therapy. 1978;3:22-30.
16. Neutel JM, Black HR, Weber MA. Combination therapy with diuretic: an evolution of understanding. Am J Med. 1996;101(3A):61S-70S.
17. Neutel JM. Metabolic manifestations of low-dose diuretics. Am J Med. 1996;101(3A):71S-82S.
18. Weir MR, Smith DH, Neutel JM, et al. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. Am J Hypertens. 2001;14(7):665-671.
19. Neutel JM, Rolf CN, Valentine SN, et al. Low-dose combination therapy as first-line treatment of mild-to-moderate hypertension: the efficacy and safety of bisoprolol/HCTZ versus amlodipine, enalapril, and placebo. Cardiovasc Rev Rep. 1996;71(11):1-9.
20. Kuschair E, Acura E, Sevilla D. Treatment of patients with essential hypertension: amlodipine 5mg/Benazepril 20mg compared with amlodipine 20mg and placebo. Clin Ther. 1996;18:6-12.
21. Messerli F, Frishman WH, Elliott WJ. Effects of verapamil and trandolapril in the management of hypertension. Trandolapril Study Group. Am J Hypertens. 1998;11(3 pt 1):322-327.
22. Frishman WH, Bryzinski BS, Coulson LR. A multifactorial trial design to assess combination therapy in hypertension. Arch Intern Med. 1994;154:1463-1470.
23. Meyers M, Asmer R, Leenen F, et al. Fixed low-dose combination therapy in hypertension - a dose response study of peridopril and indapamide. J Hypertens. 2000;18:317-325.
24. Sica DA. Fixed dose combination antihypertensive drugs. Do they have a role in rational therapy? Drugs. 1994;48(1):16-24.
25. Neutel JM, Smith DHG, Ram CVS, et al. Comparison of bisoprolol vs. atenolol for systemic hypertension in four population groups (young, old, black and non-black) using ambulatory blood pressure monitoring. Am J Cardiol. 1993;72:41-46.
26. Weber MA, Drayer JI, Nakamura DK, et al. The circadian blood pressure pattern in ambulatory normal subjects. Am J Cardiol. 1984;54:115-119.
27. Muller JE. Circadian validation in the frequency of onset of acute myocardial infarction. N Engl J Med. 1985;313:1315.
28. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation. 1989;79:733-743.
29. Willund I, Halling K, Ryden-Bergsten T, et al. Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study. Blood Press. 1997;6(6):357-364.
30. Caro JJ, Speckman JL, Salas M, et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ. 1999;160(1):41-46.
31. Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J Hum Hypertens. 1998;12:533-537.
32. Moser M. Clinical Management of Hypertension. 6th ed. Caddo, OK: Professional Communications, Inc.; 2002.
33. Chiasson JL, Gomis R, Hanefeld M, et al. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin Dependent Diabetes Mellitus. Diabetes Care. 1998;10:1720-1725.
34. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677-684.
35. Bakris G. Maximizing cardio-renal benefits in the management of hypertension: achieving blood pressure goals. J Clin Hypertens (Greenwich). 1999;1(2):141-147.
36. Chalmers J, Castaigne A, Morgan T, et al. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first line therapy in elderly hypertensive patients. J Hypertens. 2000;18: 327-337.
37. Neutel JM, Rolf CM, Valentine SN, et al. Low-dose combination therapy as first line treatment of mild to moderate hypertension: the efficacy and safety of bisoprolol/HCTZ versus amlodipine, enalapril, and placebo. Cardiovasc Rev Rep. 1996;17(ii):1-9,171-175.